Status:
WITHDRAWN
The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging
Lead Sponsor:
AgelessRx
Conditions:
Aging
Eligibility:
All Genders
18-120 years
Brief Summary
This retrospective, observational study will assess the health status of short- and long-term low-dose naltrexone (LDN) users.
Detailed Description
Long-term (\>5 years), intermediate-term (1-5 years), and short-term low-dose naltrexone (LDN) users (\<12 months) will be contacted for a retrospective, observational assessment of their health statu...
Eligibility Criteria
Inclusion
- Adults (aged 18-120)
- Any sex
- Any ethnicity
- Taking LDN
- Willing to complete health questionnaires
- Technologically competent to complete web forms
- Subgroup: willing to undergo blood testing
Exclusion
- LDN doses over 20 mg/day
- Terminal cancer patients (defined as stage IV and/or with a life expectancy of 12 months or less)
Key Trial Info
Start Date :
March 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 14 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05307627
Start Date
March 14 2022
End Date
December 14 2023
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AgelessRx
Ann Arbor, Michigan, United States, 48104